The acquisition of Asia Renal Care is expected to strengthen Fresenius Medical Care’s market position in the Asia-Pacific region, where more than 680,000 patients require regular and life-sustaining dialysis treatment.

Reportedly, in 2007 Asia Renal Care became a wholly owned subsidiary of Bumrungrad International, an associate company of Bumrungrad Hospital PCL.

Fresenius and Bumrungrad have said that the transaction will be subject to antitrust notification in Taiwan and Singapore. If approved and closed, the acquired operations will add approximately $80m in annual revenue and be accretive to earnings in the first year after closing of the transaction.

Roberto Fuste, member of the management board and chief executive officer of Asia-Pacific, said: “Through this strategic and significant acquisition, we add to our existing leading position a large business managed by professionals and valuable partners in every single market.”